We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02120807
Recruitment Status : Recruiting
First Posted : April 23, 2014
Last Update Posted : July 19, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

April 21, 2014
April 23, 2014
July 19, 2017
April 2014
April 2018   (Final data collection date for primary outcome measure)
Maximum tolerated does (MTD) [ Time Frame: 2 years ]
A standard 3+3 dose-escalation scheme will be used to test two doses of certolizumab: dose level A (200mg) and dose level B (400mg), in combination with the standard dose of chemotherapy. In addition, two de-escalation doses are planned, if dose level A proves too toxic: dose level C (chemotherapy at 75% of the standard dose + certolizumab 200mg) and dose level D (chemotherapy at 75% of the standard dose + certolizumab 400mg)..The MTD is the highest dose at which ≤ 1/6 patients experiences a DLT. Please see the dose escalation schema for exact dose level details.
Same as current
Complete list of historical versions of study NCT02120807 on ClinicalTrials.gov Archive Site
  • Progression-free survival (PFS) [ Time Frame: 2 years ]
    Patients will be followed from the first drug administration until disease progression (by RECIST 1.1) or death, whichever comes first. Patients alive who have not progressed by the end of the study time will be censored at the time of the last available follow-up. PFS probability will be estimated using Kaplan-Meier methods.
  • Immunohistochemical staining [ Time Frame: 2 years ]
    Biopsies will be performed pre- and post-treatment in all patients and will undergo immunohistochemical staining of TNF-alpha, CXCL1/2, and S100A8/9. Staining will be scored from 0-4. The difference in IHC score from post-treatment to baseline will be compared between patients who have, at minimum, evidence of stable disease during treatment (CR+PR+SD) and the remaining patients, using non-parametric Wilcoxon signed rank test.
Same as current
Not Provided
Not Provided
Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas
A Phase I Trial of Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas
The purpose of this study is to test the safety of certolizumab when it is given with the chemotherapy drugs cisplatin and pemetrexed. Cisplatin and pemetrexed are two chemotherapy drugs used in the treatment of lung cancer. The investigators want to find out what effects, good and/or bad, certolizumab has on the patient and lung cancer.
Not Provided
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Stage IV Lung Adenocarcinoma
  • Drug: Certolizumab
  • Drug: cisplatin
  • Drug: pemetrexed
Experimental: certolizumab, cisplatin and pemetrexed
Patients will receive certolizumab with 6 cycles of cisplatin & pemetrexed. Cycle of chemo will be 3 weeks. Certolizumab will be adm in the following fashion: first dose administered at the time of treatment initiation, second dose will be given after 2 weeks of treatment, third dose after four weeks of treatment, & subsequent doses given every 4 weeks thereafter. Patients will be monitored for progression of disease using RECIST 1.1 with scans to be performed every 6 weeks. Posttreatment biopsies will be performed at the time of treatment discontinuation. Two dose levels of certolizumab will be tested, 200mg & 400mg. A non-therapeutic cohort of 10 patients with adenocarcinomas who will be undergoing standard of care treatment with platinum based chemotherapy + pemetrexed +/- bevacizumab will be consented for blood draws before each cycle of treatment. This blood will be analyzed for cytokines and will serve as a reference for the experimental arm.
  • Drug: Certolizumab
  • Drug: cisplatin
  • Drug: pemetrexed
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
April 2018
April 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Previously untreated stage IV lung adenocarcinoma confirmed at MSKCC
  • Age 18 years or older
  • Karnofsky Performance Status ≥ 70
  • Patients with locally treated, stable, and/or asymptomatic brain metastases are eligible.
  • Adequate bone marrow, liver and renal function, as specified below:
  • Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
  • Hemoglobin ≥ 8 g/dL
  • Platelets ≥ 100 x 109/L
  • Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except for patients with documented Gilbert's Syndrome)
  • AST and ALT ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present
  • Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal.
  • Negative PPD test
  • For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment
  • Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafter
  • Presence of at least one site of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors
  • Archival tissue (10 Unstained Slides - 5 micron sections) from a core biopsy performed and received within 30 days before signing consent or ability to have a fresh core biopsy performed
  • Biopsy cannot be from any cytology or bone specimen
  • Biopsy site must be amenable to re-biopsy at the end of the study
  • Ability to provide written, informed consent

Exclusion Criteria:

  • Hypersensitivity to platinum agents
  • Ongoing use of investigational agents or use of investigational agents within the last four weeks
  • Prior use of agents for TNF-alpha blockade
  • History of rheumatoid arthritis, inflammatory bowel disease, or psoriatic arthritis
  • Baseline hearing deficit (CTCAE version 4.0 grade 2 or higher)
  • Ongoing bacterial, viral, or antifungal infection requiring antimicrobial treatment with the exception of thrush
  • Active tuberculosis or untreated, latent tuberculosis

    o If a patient has signs, symptoms, or a history suggestive of active tuberculosis, evaluation by an infectious disease physician will be required and active tuberculosis ruled-out prior to enrollment.

  • Acute or chronic Hepatitis B or C infection
  • Known HIV infection requiring antiretroviral medications and those with AIDS
  • Active herpes zoster infection
  • Non-healed infected skin ulcers
  • History of myocardial infarction or unstable angina within the past 12 months
  • Ongoing use of other immunosuppressive medications, including oral steroids and excluding topical steroids
  • Women who are breastfeeding Prior history of other malignancy with the exclusion of localized prostate cancer, non-melanomatous skin cancer, ductal carcinoma or lobular carcinoma in situ of the breast
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact: Paul Paik, MD 646-888-4202
Contact: Mark Kris, MD 646-888-4197
United States
Not Provided
Not Provided
Not Provided
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Paul Paik Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP